Janux Therapeutics Inc (JANX) - Total Assets
Based on the latest financial reports, Janux Therapeutics Inc (JANX) holds total assets worth $1.03 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Janux Therapeutics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Janux Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Janux Therapeutics Inc (JANX) total market value for the company's overall valuation and market capitalisation.
Janux Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Janux Therapeutics Inc's total assets of $1.03 Billion consist of 96.9% current assets and 3.1% non-current assets. Review Janux Therapeutics Inc (JANX) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.2% |
| Accounts Receivable | $6.43 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Janux Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Janux Therapeutics Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Janux Therapeutics Inc's current assets represent 96.9% of total assets in 2025, a decrease from 96.9% in 2019.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2025, down from 96.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Janux Therapeutics Inc Competitors by Total Assets
Key competitors of Janux Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Janux Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.01 | 58.47 | 43.09 |
| Quick Ratio | 17.01 | 58.47 | 43.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $943.13 Million | $1.01 Billion | $387.40 Million |
Janux Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Janux Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -5.1% |
| Total Assets | $1.01 Billion |
| Market Capitalization | $878.78 Million USD |
Valuation Analysis
Near Book Valuation: The market values Janux Therapeutics Inc's assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Janux Therapeutics Inc's assets decreased by 5.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Janux Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Janux Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.01 Billion | -5.09% |
| 2024-12-31 | $1.06 Billion | +179.05% |
| 2023-12-31 | $380.41 Million | +4.50% |
| 2022-12-31 | $364.01 Million | -4.16% |
| 2021-12-31 | $379.82 Million | +2242.13% |
| 2020-12-31 | $16.22 Million | +2288.37% |
| 2019-12-31 | $679.00K | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more